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Quality of life, cognitive, physical and emotional function at diagnosis predicts head 
and neck cancer survival: analysis of cases from the Head and Neck 5000 study. 
 
Abstract 
 
Purpose: The aim of this paper is to determine whether health-related quality of life 
(HRQOL) at diagnosis of head and neck cancer (HNC) is associated with overall 
survival following treatment with curative intent after adjusting for other factors. 
Methods: Data were collected from 5,511 participants of the Head and Neck 5000 
study (HN5000). HRQOL was measured using the EORTC QLQ-C30. Questionnaire 
and covariate data were available from 2,171 participants diagnosed as follows: oral 
cavity (655), oropharynx HPV+ (723) and HPV- (277), and larynx (516). On average, 
participants were followed up 3.2 years (sd 1.2) after diagnosis. Data were adjusted 
for age, gender, co-morbidity, intended treatment, education level, income from 
benefits, smoking status and alcohol consumption. 
Results: There was a clinically meaningful difference between Global HRQOL scores 
at diagnosis and survival in an unadjusted and adjusted model: (HR=0.86, CI=0.82-
0.89, p<0.001 (unadjusted) and HR=0.90, CI=0.86-0.94, p<0.001 (adjusted)). In 
analyses stratified by tumour site and HPV status this association was similarly noted 
before adjustment and persisted after. There were some tumour sub-site variations: 
improved survival for people with laryngeal cancer reporting higher levels of physical 
role or social functioning and people with oral cancer reporting higher levels of role 
or social functioning.  
Conclusion: As survival is the main priority for most people diagnosed with cancer, 
pre-treatment HRQOL is an additional factor to be included in risk stratification and 
case-mix adjustments. There is merit in incorporating HRQOL into routine clinical 
care as this is a useful facet in patient-clinician decision making, prognostication and 
recovery. 
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 Introduction 
 
For people diagnosed with head and neck cancer (HNC) and their carers, survival is 
an important priority [1,2]. Different studies have shown the importance of individual, 
clinical, treatment, lifestyle and social factors in predicting survival in different cancer 
types [3-6] but the influence of pre-treatment health-related quality of life (HRQOL) 
in large HNC cohorts has not previously been reported.   
 
A meta-analysis of 30 randomised controlled trials (started between 1986 and 2004) 
from the European Organisation for Research and Treatment of Cancer (EORTC) 
included survival data for 10,108 patients with 11 different cancer sites. Although set 
in the context of clinical trials and not HNC specific, this study showed that baseline 
HRQOL gave additional prognostic information over and above that derived from 
sociodemographic and clinical measures [5]. These authors also reported that, for 
people with HNC, emotional functioning, nausea and vomiting and dyspnoea 
predicted survival [6]. 
 
In a systematic review of the association between HRQOL and survival in patients 
with HNC in 19 different studies [7],  twelve studies focused on all subscales of the 
EORTC questionnaire and seven focused on selected subscales. There was strong 
evidence for a positive association between survival and pre-treatment physical 
functioning and change in global QoL from pre-treatment to six months after 
treatment. These findings are at variance to other studies [8] were there appeared to be 
some association between selected psycho-social factors and survival, however this 
relationship was not strong. There is insufficient evidence for associations between 
survival and other pre-treatment HRQOL subscales (role functioning, emotional 
functioning, cognitive functioning, social functioning and mental HRQOL). Recent 
findings from a prospective study of 109 people with HNC [9] reported an impact of 
HRQOL over a longer time frame where higher levels of HRQOL at diagnosis 
(improved physical function and reduced sleep disturbance) predicted improved 10-
year survival rates independent of clinical, individual and lifestyle factors.   
 
Although there are studies that investigate the impact of HRQOL on survival for 
people diagnosed with cancer, many of them are subject to limitations: those with 
large sample sizes are often carried out in cohorts of people with different cancers [3-
6] and those that focus on HNC are usually restricted by small samples in which it is 
difficult to stratify for tumour site and other factors. The UK based Head and Neck 
5000 study (HN5000) [10] is a prospective study of over 5000 people diagnosed with 
HNC. This cohort provides a unique opportunity to explore factors at the time of 
diagnosis that may predict survival up to three years after diagnosis of HNC. The 
large sample size allows analyses to be stratified by tumour site and helps quantify the 
place of HRQOL as a predictor of survival after adjustment for other variables. The 
aim of this paper is to determine the effect of HRQOL in predicting overall survival 
for participants in the HN5000 cohort following treatment with curative intent after 
adjusting for other associated factors.  
 
Methods 
Data were collected from participants in the Head and Neck 5000 prospective clinical 
cohort study (HN5000). Details on HN5000 have been published [10,11] and a fully 
searchable data dictionary is available online (http://www.headandneck5000.org.uk/). 
Data were collected data at diagnosis (baseline) and four and 12 months and three 
years later using self-report questionnaires and data capture forms (DCF) to record 
details from clinical records. Of the 5,511 people were consented into the study, 142 
were subsequently found to be ineligible. The resultant study sample contained 5,369 
people with head and neck cancer. 
 
Ethics 
The study was approved by the National Research Ethics Committee. 
 
Inclusion criteria 
For this study we included people diagnosed with an oral cavity, oropharyngeal or 
laryngeal tumour defined using the following ICD codes: C01, C02.4, C05.1, C05.2, 
C05.8, C05.9, C09, C10. We excluded people who did not provide a blood sample or 
consent to storage of biosamples at the time of diagnosis and therefore did not have 
serum HPV status. We also excluded people on a palliative or supportive treatment 
pathway at diagnosis. This was because we expected the relationship between quality 
of life and survival to be different in this small group of people, compared with the 
majority of people who were on a curative treatment pathway. 
 
Questionnaire 
HRQOL at diagnosis was measured using the EORTC QLQ-C30 questionnaire [12]. 
It comprises 30 questions combined into nine symptom scales, five functional 
domains and a global measure of HRQOL. For the purposes of this study we used the 
five functional domains (physical, role, emotional, cognitive and social functioning) 
and the global HRQOL as exposure variables. Scores were calculated according to 
EORTC guidelines [13] resulting in a range of 0 to 100 for each domain. Clinically 
meaningful differences in HRQOL were considered to be evident when there was a 
10-point difference in scores. 
Outcome 
The primary outcome was survival as of 1st April 2017. This was recorded via patient 
medical records and linkage to death certificate data through the UK Health and 
Social Care Information Centre (HSCIC). 
 
Confounders 
We included various demographic, clinical and health behaviour factors that may 
confound the association between HRQOL and survival. These were: age at 
diagnosis, gender, highest educational qualification and the proportion of household 
income that comes from benefits; clinical tumour, node and metastatic (TNM) stage, 
pre-treatment co-morbidity using the overall comorbidity score from the Adult 
Comorbidity Evaluation (ACE)-27 [14] and intended treatment, categorised as: 
surgery only, surgery with adjunct therapy, chemoradiotherapy only, radiotherapy 
only. Health behaviours were smoking status (current, former or never smoker) and 
alcohol consumption. Alcohol consumption was converted into standard UK alcohol 
units per week [15]. We categorised this into four categories of alcohol consumption: 
non-drinker, moderate use, harmful use and hazardous use [16]. 
 
Serum HPV testing 
We tested blood samples for HPV status. The primary measure was serological 
response to HPV antibodies using a glutathione S-transferase multiplex assay carried 
out at the German Cancer Research Centre (DKFZ) in Heidelberg, Germany [17]. We 
defined seropositivity as HPV16 E6 antibodies >1000 Median Fluorescence Intensity 
units (MFI) [17]. 
 
Statistical analysis 
We compared the data for participants with complete versus incomplete data. For 
those with complete data we stratified all analyses by tumour site, with further 
stratification by serum HPV status for people with oropharyngeal cancer. We 
described the HRQOL, demographic and clinical characteristics, and health 
behaviours of people in these four groups and compared them using ANOVAs 
(Kruskal-Wallis test for skewed data) for continuous variables and Pearson’s chi-
square test for categorical variables. For the HRQOL measures we conducted further 
post-hoc pairwise comparisons using Dunn’s test (with Bonferroni correction) for 
omnibus tests where p<0.1. 
 
We used Cox proportional hazards models to investigate the effects of different 
patient and treatment factors on the risk of death. People alive at our latest date of 
follow-up were assigned as right censored at this date. We derived hazard ratios for a 
10-point change in each of the QOL scales, which is considered to be a clinically 
meaningful difference [12] using univariable Cox regression models. We then 
adjusted the Cox models for age, gender, comorbidity, intended treatment, education, 
income from benefits, smoking status and alcohol consumption. We tested the 
proportional hazards assumption and found that TNM stage was not proportional. We 
therefore stratified our analyses by TNM stage (Table 3). 
 
To control the family wise error rate we considered a ‘family’ of statistical tests to be 
the Cox regression models within a specific tumour site (either unadjusted or 
adjusted). Using this definition, we applied a Bonferroni corrected significance level 
of 0.05/6 = 0.008. We considered all other results to be exploratory and significance 
levels for these tests were not adjusted. 
Results 
From the total H&N5000 cohort confirmed as eligible to participate (N=5,511), 4,323 
people (80.5%) were diagnosed with either oral cavity (OC), oropharyngeal (OPC) or 
laryngeal cancer (LC). We excluded 88 people on a palliative treatment pathway and 
a further 674 people who did not have HPV serology available. Consequently 3,561 
people met our inclusion criteria and comprised our study population. We analysed 
data from 2,171 (61.0%) participants who had complete HRQOL, confounder and 
outcome data (see Figure 1); the mean follow-up time was 3.2 years (SD 1.2). There 
were 440 deaths during the study period (Table 3) with a total of 6,874 person-years 
of follow-up.  
 
People with complete data differed from those without complete data across most 
exposures and confounders (Table 1). Most notably a larger proportion of people with 
complete data had HPV-positive OPC tumours and were younger with fewer or less 
severe comorbidities. People with complete data were also more likely to have never 
smoked but they did report higher alcohol consumption at the time of diagnosis. 
Differences in HRQOL between the complete and incomplete data groups were 
minor, as seen by the comparable median, and upper and lower quartiles, although p-
values were small. This reflects small differences in the relative ranking between the 
groups. 
 
Variation in QoL by tumour site  
There were small differences in global HRQOL and in the functional domains 
between people with OC, OPC (HPV±) and LC tumours at diagnosis (Table 2). 
People with OPC-HPV+ tumours having higher global HRQOL and higher physical 
functioning scores. Those with OPC-HPV+ and LC tumours had higher emotional 
functioning scores than those with OC or OPC-HPV- tumours. People with OC had 
lower cognitive function scores than those with OPC-HPV+ or LC tumours and 
people with OPC-HPV- had lower social function scores than people with either OC 
or LC tumours (Table 4). In summary, people with OPC HPV+ report better HRQOL 
in all categories than those with tumours in other oral sites. 
 
Associations between QoL and survival  
Global Quality of Life 
We found a clinically meaningful difference between Global HRQOL scores at 
diagnosis and survival in our unadjusted model when all tumour sites were analysed 
together and this difference remained after adjustment: (HR=0.86, CI=0.82-0.89, 
p<0.001 (unadjusted) and HR=0.90, CI=0.86-0.94, p<0.001 (adjusted)) (Table 3). In 
analyses stratified by tumour site and HPV status this association was similarly noted 
before adjustment and persisted after for those with OC (HR=0.84, CI=0.79-0.90, 
p<0.001 (unadjusted) and HR=0.90, CI=0.84-0.97, p=0.003 (adjusted)) or LC 
tumours (HR=0.84, CI=0.78-0.90, p<0.001 (unadjusted) and HR=0.85, CI=0.76-0.87, 
P<0.001 (adjusted)). 
 
Functional domains 
A 10-point higher score in all but the cognitive and emotional functional domains at 
diagnosis was associated with improved survival when all tumour sites were analysed 
together (Table 3). Within the tumour sub-site analyses, global HRQOL for those 
with OPC tumours (irrespective of HPV status) was not associated with survival in 
the fully adjusted model. 
 
Higher scores in physical (HR=0.79, CI=0.72-0.87, p<0.001) functioning were 
associated with improved survival in people with LC tumours. Higher scores in role 
(HR=0.91, CI=0.86-0.96, p<0.001 (OC); HR=0.87, CI=0.81-0.93, p<0.001 (LC)) or 
social functioning (HR=0.92, CI=0.87-0.97, p=0.002 (OC); HR=0.89, CI=0.83-0.96, 
P=0.001 (LC)) were associated with improved survival for people with either OC or 
LC tumours. 
 
Discussion 
In this study we used the EORTC QLQ-C30 questionnaire to examine the association 
between baseline HRQOL (global score and functional domains) and survival for 
people from the HN5000 cohort with OC, OPC (HPV±) and LC tumours.  
 
After adjusting for demographic and clinical confounders, our findings show that 
people who report higher (better) levels of HRQOL at diagnosis have a higher 
survival compared to those with lower self-reported HRQOL (associated with worse 
survival for all tumour sites). This is true for both the global HRQOL score and all 
functional domains except emotional and cognitive functioning. We also report 
tumour site-specific associations between HRQOL and survival: higher global 
HRQOL scores at baseline are associated with improved survival rates for those with 
OC and LC tumours. For people with HPV+ OPC, there was weak evidence that 
higher reported levels of physical functioning at baseline are associated with 
improved survival; however, although higher HRQOL scores are associated with 
survival in OC and LC tumours, HRQOL appears to be of limited prognostic value in 
OPC (irrespective of HPV status).  
 As in previous studies [3-7] our findings show that survival is worse in people who 
reported low levels of HRQOL (globally and in specific HRQOL domains) when their 
cancer was diagnosed.  
 
Strengths and weaknesses 
This study has several strengths. First, data from the HN5000 cohort provided a large 
sample that enabled detailed comparison between people with different types of HNC 
tumours and those with OPC diagnosed as HPV± . This is an important consideration 
as OPC is increasing and survival differs depending on whether the tumour is HPV±. 
[18,19]. Second, our analyses were adjusted for a variety of relevant clinical, 
individual and lifestyle confounders facilitating identification of the independent 
impact of HRQOL, so demonstrating the potential value of baseline HRQOL as a 
prognostic indicator.  Third, our data were collected prospectively and enabled us to 
report on survival three years after diagnosis. This is an important timescale for 
people with HNC as most cancer-related deaths are likely to have occurred by this 
time. Fourth, the EORTC QLQ-C30 is a commonly used and well-validated cancer-
related HRQOL questionnaire [12]. Finally, participants in the HN5000 cohort are 
representative of standard care reflected through recruitment from a wide range of 
hospitals including District General Hospital Specialist centres and teaching hospitals 
where they received routine care rather than being recruited from clinical trials.  
The study has several weaknesses. First, the response rate in the HN5000 study was 
satisfactory but, of those who were eligible for the study, only 61% provided 
complete data; we also acknowledge that people with poorer baseline HRQOL and 
those who were older at diagnosis were less likely to complete baseline questionnaires 
and therefore are under-represented in this analysis. Our complete data set also 
comprises a larger proportion of participants who are HPV+ than the incomplete data 
set – however, our findings suggest that, after comprehensive adjustment for relevant 
factors, HPV status has a negligible effect on the association between HRQOL and 
survival. Second, all of our hospitals were in the UK and so some may question the 
generalisability of our findings. However, we believe our data are generalisable to 
other countries because our demographic data are similar to smaller studies reporting 
HRQOL and survival [7,20,21]. 
 
Implications 
Pre-treatment HRQOL is an additional factor that informs risk stratification and case-
mix adjustments. With increasing accessibility for patients to complete patient 
reported outcomes through electronic platforms it is feasible to incorporate HRQOL 
into routine clinical care [22] This data can assist in patient-clinician decision making, 
prognostication and post-treatment recovery. Potentially by identifying patients with 
poorer HRQOL at baseline and being cognisant of the associated clinical 
characteristics, it is feasible to enhance post-treatment care and monitor more closely 
longitudinal HRQOL on an individual patient basis to facilitate early intervention. 
This could lead not only better HRQOL but improved survival. 
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Figure 1: Summary of participants with oral / oropharyngeal / laryngeal cancer with complete data 
 
 
 
 Ineligible 
n=107 
Withdrawn / ineligible = 77 
Patient choice withdrawal = 14 
Stage 0 = 16 
Consented 
n=5511 
Total OC / OPC / LC 
cases 
N=4323 
n=5404 
Excluded 
n=762 
Palliative care only = 88 
No HPV serology = 674 
Study population 
n=3561 
Total cases 
n=5404 
Complete HRQoL / 
confounder / outcome data 
N=2171 
 
Total deaths during 
study period 
n=440 
Figure
 1 
 
 
Table 1: Demographic and clinical data for people with and without complete data 
 
 Incomplete data 
(n = 1402) 
Complete data 
(n = 2171) 
p- value 
Baseline QLQ-C30 Score (25%-75%) (Score (25%-75%)  
  Global QoL 66.7 (50.0, 83.3) 66.7 (50.0, 83.3) <0.0011 
  Physical functioning 86.7 (66.7, 100.0) 93.3 (80.0, 100.0) <0.0011 
  Role functioning 83.3 (50.0, 100.0) 100.0 (66.7, 100.0) <0.0011 
  Emotional functioning 75.0 (58.3, 83.3) 75.0 (58.3, 91.7) 0.0011 
  Cognitive functioning 83.3 (66.7, 100.0) 83.3 (66.7, 100.0) 0.0041 
  Social functioning 83.3 (50.0, 100.0) 83.3 (66.7, 100.0) 0.0161 
Age (mean (SD)) 63.0 (11.0) 61.0 (10.7) <0.0012 
Gender N (%) N (%) 0.0353 
  Male 1015 (72.7) 1647 (75.9)  
  Female 381 (27.3) 524 (24.1)  
Tumour site N (%) N (%) <0.0013 
   Oral cavity 440 (31.5) 655 (30.2)  
   Oropharynx HPV- 215 (15.4) 277 (12.8)  
   Oropharynx HPV+ 364 (26.1) 723 (33.3)  
   Larynx 377 (27.0) 516 (23.8)  
Stage N (%) N (%) 0.673 
  1 322 (23.2) 518 (23.9)  
  2 260 (18.7) 380 (17.5)  
  3 180 (13.0) 265 (12.2)  
  4 627 (45.1) 1008 (46.4)  
Co-morbidity N (%) N (%) <0.0013 
   No co-morbidity 485 (34.7) 1013 (46.7)  
   Mild discompensation 515 (36.9) 713 (32.8)  
   Moderate discompensation 292 (20.9) 322 (14.8)  
   Severe discompensation 81 (5.8) 74 (3.4)  
   Unknown 23 (1.6) 49 (2.3)  
Treatment N (%) N (%) 0.0053 
   Surgery only 464 (33.2) 724 (33.3)  
   Surgery + adjunct 243 (17.4) 367 (16.9)  
   Chemoradiation only 371 (26.6) 674 (31.0)  
   Radiation only 318 (22.8) 406 (18.7)  
Education N (%) N (%) <0.0013 
   School level 256 (60.5) 976 (45.0)  
   Further education 122 (28.8) 782 (36.0)  
   University/poly 45 (10.6) 413 (19.0)  
Income from benefits N (%) N (%) 0.0723 
  None 259 (62.6) 1481 (68.2)  
  Very little 40 (9.7) 192 (8.8)  
  About a quarters 15 (3.6) 87 (4.0)  
  About half 10 (2.4) 66 (3.0)  
  About three quarters 15 (3.6) 48 (2.2)  
  All 75 (18.1) 297 (13.7)  
Table
 2 
 
Baseline Smoking   0.0083 
   Current user 102 (23.1) 410 (18.9)  
   Former 260 (59.0) 1237 (57.0)  
   Never 79 (17.9) 524 (24.1)  
Baseline Alcohol N (%) N (%) <0.0013 
   Non-drinker 163 (33.6) 551 (25.4)  
   Moderate 115 (23.7) 503 (23.2)  
   Hazardous 148 (30.5) 818 (37.7)  
   Harmful 59 (12.2) 299 (13.8)  
 
1 – P-value derived from Kruskal-Wallis test 
2 – P-value derived from ANOVA 
3 – P-value derived from Pearson’s chi-squared test 
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Table 2: A description of HRQOL, demographic, clinical, social and behavioural factors for different tumour sites 
 Oral Cavity (n = 655) Oropharynx Larynx  (n = 516) p value 
HPV-  (n = 277) HPV+  (n = 723) 
Baseline QLQ-C30 Score (25%-75%) Score (25%-75%) Score (25%-75%) Score (25%-75%)  
  Global QoL 66.7 (50.0, 83.3) 66.7 (50.0, 83.3) 75.0 (58.3, 83.3) 66.7 (50.0, 83.3) <0.0011 
  Physical functioning 93.3 (80.0, 100.0) 93.3 (73.3, 100.0) 100.0 (86.7, 100.0) 93.3 (73.3, 100.0) <0.0011 
  Role functioning 100.0 (66.7, 100.0) 83.3 (66.7, 100.0) 100.0 (66.7, 100.0) 100.0 (66.7, 100.0) 0.121 
  Emotional functioning 75.0 (58.3, 83.3) 66.7 (58.3, 83.3) 75.0 (66.7, 91.7) 75.0 (66.7, 91.7) <0.0011 
  Cognitive functioning 83.3 (66.7, 100.0) 83.3 (66.7, 100.0) 83.3 (66.7, 100.0) 83.3 (83.3, 100.0) 0.0061 
  Social functioning 83.3 (66.7, 100.0) 66.7 (50.0, 100.0) 83.3 (66.7, 100.0) 83.3 (66.7, 100.0) 0.0021 
Age 61.2 (12.2) 59.5 (9.5) 58.3 (8.7) 65.3 (10.2) <0.0012 
Gender N(%) N(%) N(%) N(%) <0.0013 
  Male 409 (62.4) 212 (76.5) 581 (80.4) 445 (86.2)  
  Female 246 (37.6) 65 (23.5) 142 (19.6) 71 (13.8)  
Stage N(%) N(%) N(%) N(%) <0.0013 
  1 256 (39.1) 36 (13.0) 11 (1.5) 215 (41.7)  
  2 147 (22.4) 35 (12.6) 56 (7.7) 142 (27.5)  
  3 44 (6.7) 45 (16.2) 98 (13.6) 78 (15.1)  
  4 208 (31.8) 161 (58.1) 558 (77.2) 81 (15.7)  
Co-morbidity N(%) N(%) N(%) N(%) <0.0013 
   No co-morbidity 293 (44.7) 114 (41.2) 404 (55.9) 202 (39.1)  
   Mild discompensation 216 (33.0) 94 (33.9) 220 (30.4) 183 (35.5)  
   Moderate discompensation 97 (14.8) 50 (18.1) 79 (10.9) 96 (18.6)  
   Severe discompensation 30 (4.6) 14 (5.1) 8 (1.1) 22 (4.3)  
   Unknown 19 (2.9) 5 (1.8) 12 (1.7) 13 (2.5)  
Treatment N(%) N(%) N(%) N(%) <0.0013 
   Surgery only 510 (77.9) 45 (16.2) 50 (6.9) 119 (23.1)  
   Surgery + adjunct 98 (15.0) 56 (20.2) 168 (23.2) 45 (8.7)  
   Chemorad only 25 (3.8) 135 (48.7) 438 (60.6) 76 (14.7)  
   Radio only 22 (3.4) 41 (14.8) 67 (9.3) 276 (53.5)  
Education N(%) N(%) N(%) N(%) <0.0013 
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   School level 279 (42.6) 116 (41.9) 291 (40.2) 290 (56.2)  
   Further education 231 (35.3) 111 (40.1) 285 (39.4) 155 (30.0)  
   University/poly 145 (22.1) 50 (18.1) 147 (20.3) 71 (13.8)  
Proportion of income from benefits N(%) N(%) N(%) N(%) <0.0013 
   None 440 (67.2) 163 (58.8) 554 (76.6) 324 (62.8)  
   Up to half 109 (16.6) 51 (18.4) 101 (14.0) 84 (16.3)  
   More than half 106 (16.2) 63 (22.7) 68 (9.4) 108 (20.9)  
Baseline Smoking N(%) N(%) N(%) N(%) <0.0013 
   Current user 148 (22.6) 109 (39.4) 52 (7.2) 101 (19.6)  
   Former 336 (51.3) 117 (42.2) 419 (58.0) 365 (70.7)  
   Never 171 (26.1) 51 (18.4) 252 (34.9) 50 (9.7)  
Baseline Alcohol N(%) N(%) N(%) N(%) <0.0013 
   Non-drinker 173 (26.4) 64 (23.1) 191 (26.4) 123 (23.8)  
   Moderate 144 (22.0) 55 (19.9) 181 (25.0) 123 (23.8)  
   Hazardous 238 (36.3) 94 (33.9) 281 (38.9) 205 (39.7)  
   Harmful 100 (15.3) 64 (23.1) 70 (9.7) 65 (12.6)  
1 – P-value derived from Kruskal-Wallis test 
2 – P-value derived from ANOVA 
3 – P-value derived from Pearson’s chi-squared test 
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Table 3: Table 3: Hazard ratios for a 10-point increase in QoL scale from unadjusted and fully adjusted Cox proportional hazards regression 
models – by tumour site 
 
 All sites Oral Cavity Oropharynx Larynx 
HPV- HPV+ 
N 2169 655 277 723 515 
Deaths (total) 440 170 75 81 114 
Global QoL      
  Unadjusted 0.86 (0.82-0.89), 
P<0.001* 
0.84 (0.79-0.90), 
P<0.001* 
0.88 (0.80-0.97), 
P=0.01 
0.93 (0.84-1.02), 
P=0.12 
0.84 (0.78-0.90), 
P<0.001* 
  Fully adjusted1 0.90 (0.86-0.94), 
P<0.001* 
0.90 (0.84-0.97), 
P=0.003* 
0.96 (0.85-1.08), 
P=0.47 
0.97 (0.88-1.08), 
P=0.63 
0.85 (0.78-0.92), 
P<0.001* 
Physical function      
  Unadjusted 0.83 (0.80-0.86), 
P<0.001* 
0.86 (0.81-0.92), 
P<0.001* 
0.87 (0.80-0.95), 
P=0.002* 
0.83 (0.75-0.91), 
P=0.001* 
0.81 (0.76-0.87), 
P<0.001* 
  Fully adjusted1 0.88 (0.84-0.93), 
P<0.001* 
0.94 (0.86-1.02), 
P=0.12 
0.95 (0.84-1.08), 
P=0.43 
0.87 (0.76-0.99), 
P=0.03 
0.79 (0.72-0.87), 
P<0.001* 
Role function      
  Unadjusted 0.91 (0.88-0.93), 
P<0.001* 
0.88 (0.84-0.92), 
P<0.001* 
0.96 (0.90-1.03), 
P=0.29 
0.95, (0.88-1.02), 
P=0.13 
0.88 (0.83-0.93), 
P<0.001* 
  Fully adjusted1 0.92 (0.90-0.95), 
P<0.001* 
0.91 (0.86-0.96), 
P<0.001* 
1.00 (0.92-1.08), 
P=0.97 
0.94 (0.87-1.01), 
P=0.10 
0.87 (0.81-0.93), 
P<0.001* 
Emotional function      
  Unadjusted 0.94 (0.91-0.98), 
P=0.003* 
0.95 (0.89-1.01), 
P=0.12 
0.94 (0.86-1.04), 
P=0.24 
1.01 (0.92-1.12), 
P=0.80 
0.93 (0.87-1.00), 
P=0.05 
  Fully adjusted1 0.95 (0.91-0.99), P=0.01 0.96 (0.90-1.03), 
P=0.29 
0.98 (0.88-1.09), 
P=0.67 
1.00 (0.90-1.12), 
P=0.95 
0.91 (0.84-0.99), 
P=0.02 
Cognitive function      
  Unadjusted 0.95 (0.91-0.98), 
P=0.004 
0.95 (0.89-1.01), 
P=0.09 
0.94 (0.87-1.03), 
P=0.19 
0.97 (0.88-1.06), 
P=0.51 
0.95 (0.87-1.02), 
P=0.17 
  Fully adjusted1 0.97 (0.93-1.01), P=0.15 1.00 (0.93-1.08), 
P=0.96 
0.95 (0.85-1.05), 
P=0.32 
0.96 (0.86-1.07), 
P=0.43 
0.94 (0.86-1.02), 
P=0.14 
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Social function      
  Unadjusted 0.91 (0.88-0.94), 
P<0.001* 
0.89 (0.84-0.94), 
P=0.001* 
0.95 (0.88-1.02), 
P=0.15 
0.94 (0.87-1.02), 
P=0.15 
0.89 (0.84-0.95), 
P<0.001* 
  Fully adjusted1 0.93 (0.90-0.96), 
P<0.001* 
0.92 (0.87-0.97), 
P=0.002* 
0.97 (0.89-1.05), 
P=0.47 
0.94 (0.86-1.02), 
P=0.14 
0.89 (0.83-0.96), 
P=0.001* 
 
1 - Adjusted for age, gender, comorbidity, treatment intent, education, income from benefits, smoking status and alcohol consumption, and 
stratified by TNM stage 
* - P-values below Bonferroni corrected significance level (0.008) 
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Table 4: Bonferroni corrected p-values from post-hoc pairwise comparisons of HRQOL by tumour site 
 
 Pairwise comparison 
 Oral cavity Oropharynx HPV- Oropharynx HPV+ 
Baseline QLQ-C30 Oropharynx HPV- Oropharynx HPV+ Larynx Oropharynx HPV+ Larynx Larynx 
  Global QoL 0.058 0.014 1.000 <0.001 0.060 0.032 
  Physical functioning 0.260 <0.001 0.206 <0.001 1.000 <0.001 
  Role functioning 0.059 0.394 0.737 0.672 0.551 1.000 
  Emotional functioning 1.000 <0.001 <0.001 0.003 <0.001 0.874 
  Cognitive functioning 0.629 0.014 0.004 1.000 0.539 1.000 
  Social functioning 0.004 0.437 1.000 0.096 <0.001 0.127 
 
 
